Objectives: The purpose of this study was to assess the safety and performance of Stellarex
Review all the Editor's Choice articles online at: http://onlinelibrary.wiley.com/ journal/10.1002/(ISSN)1522-726X/ homepage/cci_editor_s_choice_papers_and _videos.htm endpoint was primary patency, defined as freedom from restenosis with peak systolic velocity ratio 2.5 or clinically-driven target lesion revascularization (CD-TLR) at 12 months. The primary safety endpoint was freedom from device and procedure-related death through 30 days postprocedure and freedom from target limb major amputation and CD-TLR through 12 months.
Results: In total, 417 lesions were treated in 371 patients. The mean lesion length was 7.5 6 5.3 cm, 40.8% of lesions were severely calcified per core laboratory fluoroscopy criteria and 31.3% were total occlusions. Primary patency by independent duplex core lab evaluation was 81.4% and the freedom from CD-TLR was 94.8% day 365 per Kaplan-Meier estimate. The majority of patients experienced improvements in their Rutherford classification (90.3%) and walking impairment questionnaire score (83.6%) at 12 months compared to baseline.
Conclusions: This study validated previous positive findings and confirms the strong safety profile and effectiveness outcomes.
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| I N TR ODU C TI ON
Endovascular treatment of symptomatic peripheral atherosclerotic disease (PAD) of the lower extremities is the preferred and recommended treatment of choice for many patients today [1, 2] . Percutaneous transluminal angioplasty (PTA) is very effective in restoring blood flow but short-term restenosis rate due to recoil and neointimal hyperplasia is high and documented to be around 50% at 1 year in recently published trials [3, 4] . The restenosis rate is higher in occlusions and long lesions as well as in highly calcified lesions [5, 6] . Stents have been used to prevent restenosis from elastic recoil, but do not prevent neointimal hyperplasia due to the mechanical interaction of the stent and the vessel wall [6] [7] [8] . Multiple improvements in stent design were implemented to improve primary patency such as improved radial force, higher flexibility, and more resistance to stent fractures [9] . Results with paclitaxel-eluting stents in the superficial femoral artery (SFA) showed a significant improvement of primary patency as compared to bare metal stents [10, 11] . However there is still significant controversy on their role especially in the popliteal artery [12] .
Another approach in treating these lesions is the use of paclitaxelcoated angioplasty balloons where an active antiproliferative drug is delivered to the vessel wall while performing the angioplasty [13] . The absorption of an effective amount of drug into the arterial wall depends on the drug dose, coating morphology, and the excipient [14] .
Differences in drug-coated balloon (DCB) construction can lead to differences in efficacy, primary patency rates and clinically driven target lesion revascularization (CD-TLR) rates [3, 4] . Promising patency rates and target lesion revascularization rates have already been documented with this technique without the need for a permanent implant [3, 4, 15] . A limiting factor in using DCBs has been the amount of calcium in the vessel wall, due to the intrinsic limitations of an angioplasty balloon in severely calcified vessels and the potential barrier to drug absorption [16] .
The Stellarex DCB (Spectranetics Corp., Colorado Springs, CO) has a low dose (2 mg/mm 2 ) paclitaxel concentration in a hybrid-crystalline formulation coupled with the excipient polyethylene glycol (PEG), designed to limit drug loss and facilitate effective drug tissue transfer.
Initial studies on this DCB have revealed primary patency rates at 12 months of 89.5% in the First-in-Human trial [17] , 89.0% in the European Randomized Trial [18] , and 82.3% in the ILLUMENATE Pivotal Trial [19] . The freedom from CD-TLR rate was 90 to 95% in each study [17] [18] [19] . The purpose of the ILLUMENATE Global Study was to expand on these findings.
| M E TH ODS

| Study Design
The ILLUMENATE Global Study is an international, multicenter, singlearm study designed to continue to assess the safety and performance Table 1 . The trial was prospectively registered at ClinicalTrials.gov (NCT01927068).
| Procedures
Pretreatment evaluations included a clinical assessment, medical history, medication history, and assessment for study eligibility. Patients who met eligibility criteria were scheduled to undergo treatment with the DCB. Prior to the study procedure and for the duration of the study, subjects were required to receive acetylsalicylic acid (ASA) of at least 81 mg daily. According to the study protocol, patients were rec- WIQ score, EQ-5D, and duplex ultrasound. Patients' adverse events will be collected through 5 years.
| Outcomes
The primary safety endpoints were freedom from device and procedure-related death through 30 days and freedom from target 
| Data Analysis
Outcomes are reported using the intent-to-treat population, which includes all patients who were enrolled, as opposed to the per protocol analysis which excluded patients where treatment deviated from the protocol, such as stented patients or those who were not predilated.
Continuous data were reported as mean and standard deviation; categorical data were reported as frequencies and percentages. Longitudinal changes in clinical outcomes were assessed with paired t-test. The Table 2) . Lesion characteristics as assessed by the angiographic core laboratory, are presented in Table 3 . The mean lesion length was 7.5 6 5.3 cm, reference vessel diameter was 4.9 6 0.8 mm, and 31% had total occlusions. Severe calcification (assessed and defined by the core lab as calcific radiopacities noted on both sides of the arterial wall and extending more than 1 cm of length prior to contrast injection or digital subtraction) was present in 40.8% of patients. A total of 341 patients (384 lesions) completed the 12-month follow-up visit. A patient accountability flowchart is provided in Figure 1 . 
| Follow-Up Data
The freedom from a primary safety endpoint event was 94. The data were stratified by the diabetic status. Patients with diabetes were more likely to be obese (35.5% vs. 16.0%, P < 0.001), have had a previous coronary revascularization (47.2% vs. 26.4%, P < 0.001) and had more severely calcified lesions (50.3% vs. 35.5%, P 5 0.004).
Other key lesion characteristics in diabetics versus nondiabetics were: mean lesion length: 7.1 cm vs. 7.7 cm (P 5 0.230), CTO: 22.4% vs.
36.2% (P 5 0.004), and restenotic (10.2% vs. 3.7%, P 5 0.008). The primary patency rate per Kaplan-Meier estimate at day 365 in patients with diabetes was 81.0% vs. 81.5% in patients without diabetes (logrank P value 5 0.9714) ( Figure 2D ). The rates of freedom from CD-TLR at day 365 were 95.1% and 90.3%, respectively (P value by logrank 5 0.4738).
The primary patency rate at day 365 per Kaplan-Meier estimate was higher in males than females (84.5% vs.72.8%, log-rank P value 5 0.015). The rate of freedom from CD-TLR was 96.2% in males and 90.7% in females at day 365 (P value by log-rank 5 0. 0370). Baseline characteristics were similar between genders including a mean lesion length was 7.5 and 7.4 cm and total occlusion was present in 29.8% and 35.4%, in males and females, respectively. As expected, the reference vessel diameter, was larger in males (5.01 mm vs. 4.52 mm, P < 0.001).
Procedural characteristics were similar, with the exception of a higher stenting rate in males (21.0% vs. 15.0%, P 5 0.192) while the occurrence of geographic miss was lower in males (11.6% vs. 18.4%, P 5 0.067).
Geographic miss was defined by the angiographic core lab as segments proximal or distal to the treated lesion that were subjected to injury during pre and/or postdilatation but were not covered by study device.
In total, 72 lesions in 72 patients were stented. The majority were in subjects with a single treated lesion (n 5 60) while twelve subjects had an additional treated lesion that was not stented. The baseline demographics of the subjects with a stented lesion were similar to the entire cohort. Of the stented lesions, the mean lesion length was 8.5 cm, 59.2% were CTOs, and 40.3% were severely calcified. Reasons for bail-out stenting included 36 residual stenoses >50% only, 12 dissections only, and 24 both residual stenosis and dissection. However, not all of these lesions met the protocol-required degree of residual stenosis or grade of dissection (grade D or greater) for stenting based on the site-reported data. The angiographic core laboratory data were reviewed for the subjects with stented lesions. According to the core laboratory data 39 (9.4%) lesions met the protocol requirements for stenting. Per Kaplan-Meier (KM) estimate at day 365, the freedom from CD-TLR rate was 88.6% and the primary patency rate was 78.3%
for stented patients.
| D I SCUSSION
The ILLUMENATE Global Study builds on the growing body of evidence with the Stellarex DCB. The primary patency rate observed in this study was 81.4%, consistent with the 1 year primary patency rates in the ILLUMENATE FIH Study (89.5%), ILLUMENATE Pivotal Study (82.3%), and the ILLUMENATE EU RCT (89.0%) [17] [18] [19] . The primary patency rate in the DCB arms of IN.PACT SFA at 12 months was 86.6% [20] and 73.5% in LEVANT 2 [3] . The CD-TLR rate at 1 year in the ILLUMENATE Global Study was 6.2%, also consistent with results observed in ILLUMENATE Pivotal (7.9%) [19] and ILLUMENATE EU RCT (5.9%) [21] . This outcome is also comparable to 4.6% in IN.PACT SFA [22] and half the rate observed in the LEVANT 2 Study (12.3%) [3] .
This study enrolled a particularly high number of CTOs (31.3%) and the high proportion of lesions that were located within the distal femoropopliteal region; 47.1% of lesions were located in the distal SFA and popliteal artery, including 28 (13.9%) of which were located entirely within the popliteal artery. Popliteal involvement has been shown to have a significantly lower patency rate than lesions located solely in the SFA [23] .
The periprocedural stent rate was 17.3%, higher than in IN.PACT SFA (7.3%) and LEVANT 2 (2.5%). ILLUMENATE Pivotal reported a stent rate of 6.0% and in ILLUMENATE EU RCT it was 15.4%. Periprocedural stent rates are inconsistent over different studies without a definitive explanation other than investigator dependency. Assessment of angiographic core lab data within this study indicted 9.4% of lesions treated met the predefined criteria for bail-out stenting. Therefore, the stenting rate does not appear to be related to the performance of the study device, but rather due to investigator treatment practices.
Notably, the primary patency in patients with diabetes was similar to those without diabetes. The patency rates were 81.0% and 81.5%, respectively (P 5 0.9714 by log rank). These outcomes are consistent with the data observed in the ILLUMENATE EU RCT Trial [21] . Previous reports have shown diabetes to increase the risk of restenosis in patients undergoing endovascular treatment with PTA and/stenting or DCB [23, 24] .
The primary patency rate in males was significantly higher than females (84.5% vs. 72.8%, log-rank P value is 0.015). This difference between groups is inconsistent with findings from the two previous trials on the same DCB. In the ILLUMENATE Pivotal Study, a significant treatment effect was observed in both females and males after use of the Stellarex DCB as compared to PTA with no significant difference in primary patency between the genders (80.9% in males vs. 84.1% in females, log rank P value 5 0.4851). Likewise, there was no statistical difference in the primary patency rates observed in the ILLUMENATE EU RCT Study when stratified by gender (90.4% in males and 85.3% in females, P 5 0.3064) [21] . The only differences in vascular characteristics we could identify was a larger reference vessel diameter in males (5.016 0.86 vs. 4.52 6 0.69, P < 0.001). Lesion length and number of CTOs were similar in males and females. We know vessel diameter and lesion length are directly related to vessel patency after treatment [25] .
The angiographic core lab reported geographic miss occurring in females in 18.4% of cases versus 11.6% in males P 5 0.067, also a predictor of primary patency failure [26] . While inconsistent with previous trials on this DCB, these findings are not unusual. Female gender was an independent predictor of restenosis in a retrospective analysis of 260 patients treated with the IN.PACT Admiral or Pacific DCBs [23] .
Within the LEVANT 2 study the female cohort had a higher patency rate when treated with an uncoated PTA catheter than with the Lutonix DCB. More investigational work needs to be done to understand the impact of gender on outcomes with DCB treatment in these arteries.
DCB performance and pharmacokinetic profiles differ because of differences in the balloon platform, excipients, drug concentrations, coating morphology, drug solubility, and coating methods [14, 27, 28] . A class effect for DCBs has not been shown, therefore each DCB has to be evaluated and outcomes from one cannot be generalized to another.
The Stellarex DCB utilizes a low dose of paclitaxel (2 mg/mm 2 ) in a hybrid formulation made of both amorphous and crystalline constituents combined with a polyethylene glycol (PEG) excipient. The hybrid formulation helps maintain coating integrity compared to pure crystalline while allowing for sustained drug tissue release [14] .
Limitations of this study include the trial design being nonblinded and single-arm. Additionally, adjunctive devices such as atherectomy
were not assessed and outcomes cannot be generalized beyond lesions that can be successfully predilated with PTA. Longer term follow-up data will be critical to understand the durability of this treatment.
| C ONC LUSI ON S
The ILLUMENATE Global Study is a large prospective, multicenter, single-arm study using the Stellarex DCB in SFA and/or popliteal arteries down to the trifurcation. The results reported for this study are consistent with the previously reported data with this DCB. The data confirm the high primary patency rate and strong safety profile of the Stellarex DCB.
